Allogene – ALPHA3 Interim Analysis Incoming

Summary Allogene Therapeutics announced it will present an interim futility analysis from its pivotal Phase 2 ALPHA3 trial of an allogeneic CAR-T therapy in first-line consolidation for large B-cell lymphoma (LBCL), with data expected on April 13, 2026. What Happened On April 10, Allogene stated…